Inactive Instrument

All News Checkmate Pharmaceuticals, Inc.

Equities

CMPI

US1628181083

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

Regeneron Completes Checkmate Pharmaceuticals Deal, Triggers $5 Million Milestone Payment to Kuros Biosciences	22-06-02	MT
Kuros To Receive $5 Million Milestone Payment from Regeneron's Acquisition Of Checkmate	22-06-02	MT
Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment	22-06-02	AQ
Checkmate Pharmaceuticals : Completion of Acquisition or Disposition of Assets - Form 8-K	22-05-31	PU
CHECKMATE PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	22-05-31	AQ
Checkmate Pharmaceuticals, Inc. Appoints Robert E. Landry as Chief Financial Officer	22-05-31	CI
Checkmate Pharmaceuticals, Inc. Announces Board Changes	22-05-31	CI
Checkmate Pharmaceuticals, Inc.(NasdaqGM:CMPI) dropped from NASDAQ Composite Index	22-05-31	CI
Checkmate Pharmaceuticals, Inc.(NasdaqGM:CMPI) dropped from S&P TMI Index	22-05-31	CI
Regeneron Pharmaceuticals, Inc. completed the acquisition of Checkmate Pharmaceuticals, Inc. from Decheng Capital China Life Sciences USD Fund III, L.P., a fund managed by Decheng Capital LLC, Arthur Krieg and others.	22-05-26	CI
University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting	22-05-26	GL
University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting	22-05-26	AQ
University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology Annual Meeting	22-05-26	CI
CHECKMATE PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI	22-05-17	BU
CHECKMATE PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	22-05-12	AQ
Checkmate Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update	22-05-12	GL
Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update	22-05-12	AQ
CHECKMATE PHARMACEUTICALS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI	22-05-05	BU
Kuros Biosciences' Q1 Medical Devices Sales Surge 102% Following US FDA Approval For MagnetOs	22-04-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Checkmate Pharmaceuticals, Inc.

Equities

CMPI

US1628181083

All News

Filters